23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and rat studies suggest a thiazole sulfone-based disruptor of the GCK- GCKR complex could help treat Type II diabetes. Chemical synthesis and in vitro testing of aryl sulfone analogs...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Advinus, Takeda deal

Advinus received a $3 million milestone payment from Takeda under a 2012 deal to discover compounds against predefined undisclosed targets for inflammation, CNS and metabolic diseases. Advinus said this is the second milestone under the...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Advinus, Takeda deal

Advinus received a $3 million milestone payment from Takeda under a 2012 deal to discover compounds against predefined undisclosed targets for inflammation, CNS and metabolic diseases. Advinus said this is the "first year milestone" under...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

SignalChem Lifesciences management update

SignalChem Lifesciences Corp. , Richmond, B.C.   Business: Cancer, Neurology, Inflammation   Hired: Akash Mathur as CBO, formerly VP and global head of business development at Advinus Therapeutics Ltd. ; and Darren Ready as CFO,...
08:00 , Nov 21, 2013 |  BC Innovations  |  Cover Story

Glucokinase alternative

Over the last decade, numerous compounds that activate glucokinase have advanced into the clinic to treat diabetes, but the approach has faced safety challenges because of, amongst other issues, high rates of adverse hypoglycemic events....
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Epidermal growth factor receptor (EGFR); Janus kinase-2 (JAK-2); PTEN (MMAC1; TEP1) In vitro and mouse studies suggest allosteric inhibition of JAK-2 could help...
07:00 , Jul 11, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Last month's public-private partnership with the highest total funding was the launch of the Global Health Innovative Technology Fund , an infectious disease initiative that plans to disperse $100 million over 5 years. On the...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Advinus, H. Lee Moffitt Cancer Center deal

Advinus partnered with the cancer center to develop two early stage targeted cancer programs discovered by Moffitt. The programs include a disruptor of the interaction between retinoblastoma (RB) and CRAF (RAF1) and an inhibitor of...
07:00 , May 6, 2013 |  BioCentury  |  Strategy

Doubling down in diabetes

Against a backdrop of flattening sales of its only marketed diabetes drugs and a new class of oral drugs - SGLT2s - entering the market from competitors, Merck & Co. Inc. appears to be shoring...